Detalhe da pesquisa
1.
IFN-α Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T-Cell Proliferation.
J Infect Dis
; 222(1): 148-157, 2020 06 16.
Artigo
Inglês
| MEDLINE | ID: mdl-32049318
2.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.
Antimicrob Agents Chemother
; 64(7)2020 06 23.
Artigo
Inglês
| MEDLINE | ID: mdl-32393496
3.
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Liver Int
; 36(4): 505-14, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26519669
4.
Reduction of HBV replication prolongs the early immunological response to IFNα therapy.
J Hepatol
; 60(1): 54-61, 2014 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-23994382
5.
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Gastroenterology
; 142(4): 790-5, 2012 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-22248659
6.
First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers.
Clin Transl Sci
; 16(9): 1653-1666, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37350225
7.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection.
Open Forum Infect Dis
; 9(2): ofab630, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-35106315
8.
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Lancet
; 376(9751): 1467-75, 2010 Oct 30.
Artigo
Inglês
| MEDLINE | ID: mdl-20951424
9.
Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.
Nat Med
; 27(11): 1961-1969, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34750553
10.
Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.
Antimicrob Agents Chemother
; 53(11): 4753-61, 2009 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-19721074
11.
Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.
Drug Saf
; 31(12): 1097-114, 2008.
Artigo
Inglês
| MEDLINE | ID: mdl-19026027
12.
Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects.
J Clin Pharmacol
; 47(6): 689-96, 2007 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-17456583
13.
Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
Antivir Ther
; 19(3): 259-67, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24256626
14.
Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review.
Adv Ther
; 29(10): 826-48, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23054689
15.
In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite.
Eur J Pharmacol
; 628(1-3): 6-10, 2010 Feb 25.
Artigo
Inglês
| MEDLINE | ID: mdl-19917275